AR067627A1 - Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion - Google Patents

Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion

Info

Publication number
AR067627A1
AR067627A1 ARP080102744A ARP080102744A AR067627A1 AR 067627 A1 AR067627 A1 AR 067627A1 AR P080102744 A ARP080102744 A AR P080102744A AR P080102744 A ARP080102744 A AR P080102744A AR 067627 A1 AR067627 A1 AR 067627A1
Authority
AR
Argentina
Prior art keywords
alkyl
radical
attached
preparation procedure
compound
Prior art date
Application number
ARP080102744A
Other languages
English (en)
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of AR067627A1 publication Critical patent/AR067627A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/164—Unsaturated ethers containing six-membered aromatic rings
    • C07C43/168—Unsaturated ethers containing six-membered aromatic rings containing six-membered aromatic rings and other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Conjugados poliméricos basados en Fmoc (9-fluorofenil-metoxicarbonilo). Estos conjugado9s son utiles para extender la circulacion in vivo de drogas con proteínas y péptidos. Reivindicacion 1: Un compuesto de la formula 1 caracterizado porque Z es un grupo saliente y al menos uno de la posicion 1, 2, 3, 4, 5, 6, 7 u 8 está unido al radical Y; Y es un radical que contiene un biopolímero semi-sintético que está unido a una mitad N-succinimidilo; al menos uno de una posicion disponible 1, 2, 3, 4, 5, 6, 7 u 8 está unido opcionalmente al radical X; X es -SO3-R3; R3 está seleccionado independientemente del grupo que consiste en hidrogeno, alquilo C1-8 y alquil C1-8-R4; y R4 es un polímero. Reivindicacion 2: El compuesto de acuerdo con la reivindicacion 1, caracterizado porque Z es un éster de N-succinimidilo; Y es como en formula (2), polímero es un biopolímero semi-sintético; R1 es en cada caso independientemente un alquilo C1-8; y R2 es seleccionado independientemente del grupo que consiste en -C(O)NR-, -C(O)NR-alquil C1-8-NR-, -NRC(O)- y -NRC(O)-alquil C1-8-NR; R es independientemente hidrogeno o alquilo C1-8. Reivindicacion 14: Un conjugado caracterizado porque comprende el compuesto de cualquiera de las reivindicaciones 1 a 7 y una droga con proteína o péptido.
ARP080102744A 2007-06-26 2008-06-25 Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion AR067627A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93716907P 2007-06-26 2007-06-26
US12326308P 2008-04-07 2008-04-07

Publications (1)

Publication Number Publication Date
AR067627A1 true AR067627A1 (es) 2009-10-21

Family

ID=39855055

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102744A AR067627A1 (es) 2007-06-26 2008-06-25 Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion

Country Status (16)

Country Link
US (3) US7700551B2 (es)
EP (1) EP2173383B1 (es)
JP (1) JP5622569B2 (es)
KR (1) KR101654375B1 (es)
CN (1) CN101687048B (es)
AR (1) AR067627A1 (es)
AU (1) AU2008267360B2 (es)
BR (1) BRPI0813772A2 (es)
CA (1) CA2690554C (es)
DK (1) DK2173383T3 (es)
ES (1) ES2644453T3 (es)
HK (1) HK1142828A1 (es)
MX (1) MX2009013682A (es)
NZ (1) NZ582669A (es)
TW (1) TWI569810B (es)
WO (1) WO2009000522A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101821B1 (en) 2006-12-15 2014-08-13 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
AR067627A1 (es) * 2007-06-26 2009-10-21 Baxter Int Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
NZ597600A (en) 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
SG10201401194VA (en) 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
EP2459224B1 (en) * 2009-07-27 2016-06-01 Baxalta GmbH Blood coagulation protein conjugates
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
NZ612320A (en) 2010-12-22 2015-06-26 Baxter Healthcare Sa Materials and methods for conjugating a water soluble fatty acid derivative to a protein
RU2014103185A (ru) 2011-07-18 2015-08-27 Артс Байолоджикс А/С Биологически активное соединение на основе лютеинизирующего гормона (lh) с пролонгированным действием
EP2846822A2 (en) 2012-05-11 2015-03-18 Prorec Bio AB Method for diagnosis and treatment of prolactin associated disorders
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680295B1 (en) * 1994-09-22 2004-01-20 The Administrators Of The Tulane Educational Fund Method and pharmaceutical composition for prevention and treatment of brain damage
US6368814B1 (en) * 2000-12-22 2002-04-09 Roche Diagnostics Corporation Tricyclic antidepressant derivatives and immunoassay
JP4698579B2 (ja) * 2003-04-08 2011-06-08 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 可逆的ｐｅｇ化薬物
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
RU2327703C2 (ru) * 2003-08-12 2008-06-27 Лайпоксен Текнолоджиз Лимитед Производные полисиаловой кислоты
JP4942014B2 (ja) * 2004-09-14 2012-05-30 独立行政法人産業技術総合研究所 Ｏ−結合型糖アミノ酸
DK1835938T3 (da) * 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
EP1896082B1 (en) * 2005-06-16 2012-12-26 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
EP2101821B1 (en) * 2006-12-15 2014-08-13 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
EP2114458B1 (en) * 2006-12-27 2014-02-26 Nektar Therapeutics Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage
AR067627A1 (es) * 2007-06-26 2009-10-21 Baxter Int Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion

Also Published As

Publication number Publication date
JP5622569B2 (ja) 2014-11-12
BRPI0813772A2 (pt) 2014-12-30
MX2009013682A (es) 2010-08-31
KR101654375B1 (ko) 2016-09-05
ES2644453T3 (es) 2017-11-29
CA2690554A1 (en) 2008-12-31
KR20100039854A (ko) 2010-04-16
US7700551B2 (en) 2010-04-20
JP2010531371A (ja) 2010-09-24
CN101687048A (zh) 2010-03-31
CA2690554C (en) 2016-08-16
CN101687048B (zh) 2013-02-27
HK1142828A1 (en) 2010-12-17
US20100121028A1 (en) 2010-05-13
US20100121034A1 (en) 2010-05-13
EP2173383A1 (en) 2010-04-14
WO2009000522A1 (en) 2008-12-31
EP2173383B1 (en) 2017-08-09
US8445544B2 (en) 2013-05-21
TWI569810B (zh) 2017-02-11
US20090005542A1 (en) 2009-01-01
AU2008267360B2 (en) 2013-09-12
NZ582669A (en) 2011-07-29
AU2008267360A1 (en) 2008-12-31
DK2173383T3 (en) 2017-09-25
TW200908996A (en) 2009-03-01

Similar Documents

Publication Publication Date Title
AR067627A1 (es) Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
DE602007011901D1 (de) Ptiden und zellpenetrierenden peptiden gekoppelt a
EP2573110A3 (en) Peptide vaccines with Seq Id No: 174, 178, 186 or 194 for cancers expressing tumor-associated antigens
Tian et al. Effect of stapling architecture on physiochemical properties and cell permeability of stapled α‐helical peptides: a comparative study
CY1118243T1 (el) Νεα κατασκευασματα μεταφορεα και μορια συζευγματος φορτιου μεταφορεα
BR112012008142A2 (pt) conjugados de peptídeo/ polietilenoglicol liga dos a dissulfeto para a transfecção de ácidos nucleicos
RU2016144055A (ru) Конъюгаты лекарственного средства с наночастицами
ATE533514T1 (de) Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpern
AR055179A1 (es) Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas
CY1113684T1 (el) Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη
BR112015004501A2 (pt) derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo
ATE499070T1 (de) Saugstent
CO6210831A2 (es) Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
WO2018091544A8 (en) SUBSTANCES FOR TARGETING VARIOUS SELECTED ORGANS OR TISSUES
KR20170085593A (ko) 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도
SE0402925D0 (sv) Novel Compounds
CN117567639A (zh) 用于细胞内递送装订肽的多肽缀合物
WO2011008863A3 (en) Stereoisomer peptides and their polymer conjugates for hiv disease
ATE555120T1 (de) Neue antimikrobielle peptide und ihre anwendung
NI200700176A (es) Compuestos peptídicos
UY26492A1 (es) Bencimidazoles, su preparación y su empleo como medicamentos.
Dahiya Total synthesis and biological potential of psammosilenin A
ES2607498T3 (es) Peptidomiméticos que poseen actividad biológica fotocontrolada

Legal Events

Date Code Title Description
FB Suspension of granting procedure